The National Pharmaceutical Pricing Authority (NPPA) has released draft version of proposed retail price calculation for five formulations, including a combination of telmisartan IP 40 mg and amlodipine besylate IP, which has a moving annual total (MAT) of Rs. 596.8 crore.
Enforcement Report - Week of February 19, 2020
Acharya Chemicals Fails EDQM Inspection
After 2018 saw numerous sartan drugs recalled for possible carcinogenic impurities, in 2019, the industry kept an eye on the regulatory issues that followed and the breakthroughs that have mitigated some of the risks.
Cipla`s Generic Amlodipine Besylate; Benazepril Hydrochloride Receives Approval in US
Sciegen Pharms` Amlodipine Besylate; Olmesartan Medoxomil Receives Approval in US
Valsartan products not currently recalled - Updated November 27, 2018
Enforcement Report - Week of October 17, 2018
Accord Healthcare's Generic Amlodipine Besylate; Olmesartan Medoxomil Receives Approval in US